Fig. 7
From: The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes
NK-PSS-M demonstrates robust performance in extreme scenarios and a recommended application strategy. (A-C) Comparison of the predictive performance of NK-PSS-M, IPSS-M, and IPSS-R when the gene panel only includes CEBPA, U2AF1, and RUNX1. (A-B) The balloon plots show the changes in IPSS-M prediction results in the training and validation cohorts, respectively. (C) C-index values of each model in the training and validation cohorts. (D-E) Evaluation of the predictive performance of NK-PSS-M, IPSS-M, and IPSS-R in patients with mutations other than the three genes. (D) Proportion of patients with different mutation status. (E) C-index values of each model in the training and validation cohorts. (F) A recommended application strategy for NK-PSS-M in clinical practice